checkAd

     115  0 Kommentare Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch - Seite 3

    1 2020 Physician (n=46) and Patient (n=190) surveys conducted in the EU by third-party market research firm on behalf of Pulse Biosciences, Inc.

    Lesen Sie auch


    Business Wire (engl.)
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von Business Wire (engl.)
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch - Seite 3 Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced that the first CellFX procedures in the European Union were successfully completed. The initial …